You’ve seen the headlines. Another biotech startup raises $200 million to “revolutionize drug discovery with AI.” The pitch decks are beautiful. The algorithms are supposedly brilliant. The promises are endless. And almost all of them are completely missing the point.
We aren’t suffering from a lack of technological magic in drug discovery; we are suffering from a fundamental, embarrassing ignorance of how diseases actually work.
We are pouring billions into artificial intelligence, machine learning, and high-throughput screening, hoping these tools will magically spit out cures. But technology is not a substitute for understanding. It is merely an accelerator. If you don’t know where you’re going, a faster car just gets you lost quicker.
You cannot computationally simulate your way out of a biological misunderstanding.
Think about the reality of clinical trials today. Phase II failures are the norm, not the exception. Why? Because we are treating the symptoms of our ignorance with software. We identify a target, design a molecule with AI, and hope for the best. But when that molecule actually enters a human body, it often fails because our underlying hypothesis about the disease mechanism was completely wrong.
Investors love computational platforms because they scale like software. But biology doesn’t scale like software. Biology is wet, messy, and deeply personal. The “magic wand” mentality is a trap. It feels good to invest in shiny tech, but it ignores the painstaking, unglamorous reality of medical research.
Funding a computational platform without understanding the disease mechanism is like buying a Ferrari to drive through a dense jungle. You have a lot of horsepower, but you’re still stuck in the mud.
The real bottleneck isn’t screening molecules faster. It’s understanding the disease itself. It’s patient-level phenotyping. It’s mechanistic biology. It’s the “dull” science that no one markets on Twitter or features in glossy investor decks.
If you are placing bets in biotech, pharma, or healthcare investing, you need to reframe your strategy. The highest-leverage investment isn’t the next AI drug discovery platform. It is the slow, patient capital that funds basic disease biology.
The highest-leverage investment in pharma isn’t the next AI platform; it’s the painstaking, unglamorous study of why a disease happens in the first place.
This is hard to hear. It defies the quick-fix narrative. It requires patience in an era of instant gratification. But if we actually want to cure diseases instead of just generating buzz, we have to abandon the search for magic wands.
Stop looking for magic wands. Pick up a scalpel and start doing the dirty work.
FAQ
Q: Isn't AI actually speeding up the discovery of new drug targets?
A: AI is great at finding patterns, but if the underlying biological data is flawed, you just get faster bad answers. AI cannot invent biological understanding that doesn't exist yet.
Q: What should investors be funding instead of AI drug discovery platforms?
A: Patient capital needs to flow into deep, mechanistic disease biology and patient-level phenotyping. It’s unglamorous and slow, but it’s the only way to build the foundational knowledge AI needs to actually succeed later.
Q: Are you saying computational tools have no place in pharma?
A: Not at all. Computational tools are powerful accelerators, but they are useless without a steering wheel. We are currently over-indexing on the engine and completely ignoring the map.